Absatou BA/KY¹*, Issa Tondé², Arnaud Dienderé¹, Idriss Traore¹, André KY³, Souleymane Yameogo¹, Salimata Diallo¹, Issoufou Ouedraogo¹ and Idrissa Sanou⁴

¹University Hospital of Bogodogo, Burkina Faso
²Charles De Gaulle University Children’s Hospital/Ouagadougou, Burkina Faso
³World the Vision, Burkina Faso
⁴University Hospital of Tengadogo, Burkina Faso

*Corresponding Author: Absatou BA/KY, Bacteriology-Virology Unit of the University Hospital of Bogodogo (CHU-B), Burkina Faso.

Received: March 27, 2025; Published: April 04, 2025

Abstract

Introduction: Meningococcal meningitis is a major public health issue in Burkina Faso due to its high morbidity and mortality. This work aims at studying meningococcal meningites thirteen years (13 years) after the nationwide introduction of” MenAfrivac” serogroup A meningococcal vaccine.

Methodology: This was a retrospective cross-sectional study of all epidemiological surveillance data on meningococcal meningitis following the introduction of conjugate A vaccine from 2010 to 2022. It involved all suspected cases of meningitis in Burkina Faso's 13 health regions, whose cerebrospinal fluid (CSF) samples were analyzed in the laboratory using the Polymerization Chain Reaction (PCR) technique.

Results: A total number of 27370 suspected cases of meningitis were recorded. Of these, 3125 were PCR-confirmed, including 1155 meningococcal cases, i.e. a frequency of 36.96%, and 76 fatal cases, of which 56 (73.68%) were due to serogroup W. Patients aged [4 - 15] were the most represented (74.12%). Nm serogroups accounted for 0.41% of NmA, 75.17% of NmW and 20.78% of NmX.

Conclusion: This work has highlighted the nearly total disappearance of NmA following the introduction of the A(MenAfrivac) conjugate vaccine, and the emergence and re-emergence of other serogroups. It is therefore imperative to strengthen surveillance, develop and make available a conjugate vaccine that takes into account these serogroups noticed in the country.

Keywords: Meningococcal Meningitis; Serogroups A; W and X; MenAfriVac

References

1. Lapeyssonnie L. “Cerebrospinal Meningitis In Africa”. Bulletin of the World Health Organization 28 (1963): 3-114.
2. Greenwood B and Manson Lecture. “Meningococcal meningitis in Africa”. Transactions of the Royal Society of Tropical Medicine and Hygiene 93 (1999): 341-353.
3. Greenwood B and Manson L. “Meningococcal meningitis in Africa”. Transactions of the Royal Society of Tropical Medicine and Hygiene 93 (1999): 341-353.
4. World Health Organization. “Control of epidemic meningococcal disease”. In: Practical Guidelines. 2nd ed. World Health Organization, Geneva (1998).
5. World Health Organisation. “Multi Disease Surveillance Center (MDSC), WHO/African region”. Meningitis Weekly Bulletin.
6. Iliyasu G., et al. "Response to the meningococcal meningitis epidemic (MME) at Aminu Kano Teaching Hospital, Kano (2008-2009)”. Nigerian Journal of Medicine4 (2009): 428-430.
7. World Health Organization. “Control of epidemic meningococcal disease”. WHO practical guidelines, 2nd edition. (2013).
8. Ky-Ba A., et al. "Dynamics of germs responsible for acute bacterial meningitis in Burkina Faso in the last ten years (2005-2014)”. African Journal of Clinical and Experimental Microbiology1 (2016): 10-17.
9. World Health Organisation. “Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives”. The Weekly Epidemiological Record 88 (2013): 129-136.
10. World Health Organisation. “Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitides serogroup C in Africa: recommendations from a WHO expert consultation”. The Weekly Epidemiological Record 90 (2015): 633-636.
11. Umaru ET., et al. "Risk factors responsible for the spread of meningococcal meningitis: a review”. International Journal of Education and Research 1 (2013): 1-30.
12. Sacko A. "Impact de la campagne de vaccination menafrivac sur l’épidémiologie des méningites cérébrospinales au Mali". Thèse Médecine, USTTB (2016): 1-78.
13. Doumbia S. "Aspects épidémiologiques et bactériologiques de la méningite dans le district de Bamako avant et après l’introduction du MenAfriVac : Etude comparative des données des périodes de (2009-2010) et (2011-2012)". Thèse de Médecine (2013): 1-55.
14. JR., et al. "Neisseria meningitidis sérogroupe W, Burkina Faso, 2012". Emerging Infectious Diseases 20 (2014): 394-399.
15. Ouédraogo SM., et al. "Acute Bacterial Meningitis with soluble antigen detected by LPA test at the Souro-Sanou University Hospital of Bobo-Dioulasso (Burkina Faso)". Medecine et Sante Tropicales4 (2013): 412-416.
16. Dukic V., et al. "The Role of Weather in Meningitis Outbreaks in Navrongo, Ghana: A Generalized Additive Modeling Approach”. Journal of Agricultural, Biological and Environmental Statistics 3 (2012): 442-460.
17. García-Pando CP., et al. "Soil Dust Aerosols and Wind as Predictors of Seasonal Meningitis Incidence in Niger”. Environmental Health Perspectives7 (2014): 679-686.
18. Umaru TE., et al. "Effects of Urban Sprawl on Meningococcal Meningitis Incidence in Kaduna Urban Area, Nigeria”. Research on Humanities and Social Sciences8 (2015): 1-14.
19. Kouyaté F. "Aspect épidémiologiques des méningites cérébrospinales dans le service des Maladies Infectieuses au CHU du Point G de janvier 2011 à décembre 2014". Thèse, de Médecine USTTB (2016): 1-80.
20. World Health Organisation. “Meningococcal disease in countries of the African meningitis belt, 2012 - emerging needs and future perspectives”. The Weekly Epidemiological Record 88 (2013): 129-136.
21. Collard JM., et al. "Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination”. BMC Infectious Disease 13 (2013): 43.
22. Abass H. "Epidémies de méningite avant et après l’introduction du vaccin méningococcique conjugué monovalent contre le sérogroupe A dans la ceinture africaine de la méningite. Maladies émergentes". Université Pierre et Marie Curie - Paris VI (2017): 1-99.
23. Guindo I., et al. "Clones des souches de Neisseria meningitidis au Mali (in French)". Médecine et Maladies Infectieuses 41 (2011): 7-13.
24. Kristiansen PA., et al. "Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine”. BMC Infectious Disease 13 (2013): 2-10.
25. Caugant DA., et al. "Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine”. PLoS One 7 (2012): 1-9.
26. Ouangraoua S. "Profil épidémiologique des méningites bactériennes aigues avant et après l’introduction du vaccin conjugue “A” dans quatre (4) régions de l’ouest du Burkina Faso », Mémoire de Diplôme Inter universitaire (DIU) International de vaccinologie". INSSA (2012): 1-36.
27. Delrieu I., et al. "Emergence de l’épidémie de méningite à Neisseria meningitidis du sérogroupe X au Togo et au Burkina Faso". PLoS One 6 (2011): 1-8
28. Funk A., et al. "Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-2014”. PLoS Current 29 (2014): 6.
29. Daugla DM., et al. "Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study”. Lancet 383 (2014): 40-47.
30. Gamougam K., et al. "Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013”. Emergency Infectious Diseases1 (2015): 115-118.
31. Novak RT., et al. "Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data”. Lancet Infectious Diseases10 (2010): 757-764.
32. Kristiansen PA., et al. "Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac”. BMC Infectious Diseases 14 (2014): 663, 1-11.
33. MenAfriCar consortium. “The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group A meningococcal conjugate vaccine”. Journal of Infectious Diseases8 (2015): 1298-1307.
34. World Health Organisation. “Meningococcal disease”. The Weekly Epidemiological Record 13 (2015): 121-132.
35. Boisier P., et al. "Meningococcal meningitis: nprecedented incidence of serogroup X-related cases in 2006 in Niger”. Clinical Infectious Diseases5 (2007): 657-663.
36. Gagneux SP., et al. "Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana”. Journal of Infectious Diseases 5 (2002): 618-626.
37. Koumaré B., et al. "The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002”. Vaccine 1 (2007): 37-41.
38. Djibo S., et al. "Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000”. Tropical Medicine and International Health12 (2003): 1118-1123.
39. Traoré Y., et al. "The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005”. Clinical Infectious Diseases 7 (2006): 817-822.
40. Ba AK., et al. "Evolution du portage méningococcique dans les sérogroupes X et Y avant introduction de MenAfriVac dans le district sanitaire de Kaya, Burkina Faso". Maladies infectieuses BMC 14 (2014):

Citation

Citation: Absatou BA/KY., et al. “Impact of « MenAfrivac» on Meningococcal Meningitis from 2010 to 2022 in Burkina Faso".Acta Scientific Microbiology 8.5 (2025): 02-14.

Copyright

Copyright: © 2025 Absatou BA/KY., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.